Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis

Suda, G; Baba, M; Yamamoto, Y; Sho, T; Ogawa, K; Kimura, M; Hosoda, S; Yoshida, S; Kubo, A; Fu, QJ; Yang, ZJ; Tokuchi, Y; Kitagataya, T; Maehara, O; Ohnishi, S; Yamada, R; Ohara, M; Kawagishi, N; Natsuizaka, M; Nakai, M; Morikawa, K; Furuya, K; Suzuki, K; Izumi, T; Meguro, T; Terashita, K; Ito, J; Kobayashi, T; Tsunematsu, I; Sakamoto, N

Suda, G (通讯作者)，Touei Naika Clin, Grad Sch Med, Dept Gastroenterol, North 15,West 7,Kita Ku, Sapporo, Hokkaido 0608638, Japan.;Suda, G (通讯作者)，Hokkaido Univ, Grad Sch Med, Dept Hepatol, North 15,West 7,Kita Ku, Sapporo, Hokkaido 0608638, Japan.

JOURNAL OF MEDICAL VIROLOGY, 2023; 95 (2):

Abstract

No prospective study on the efficacy of tenofovir alafenamide (TAF), a novel tenofovir prodrug, in preventing hepatitis B virus (HBV) reactivation has......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索